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Podocyte foot process effacement is not correlated with the
level of proteinuria in human glomerulopathies.
Background. Nephrotic syndromes result from increased
glomerular permeability to proteins and are structurally be-
lieved to be associated with podocyte foot process effacement.
Despite increasing knowledge of the molecular composition of
the glomerular filtration barrier, the relationship between pro-
teinuria and foot process effacement is unclear.
Methods. We conducted a morphologic study on the rela-
tionship between podocyte foot process effacement and pro-
teinuria. Electron microscope pictures of glomerular capillaries
were randomly taken from 27 cases in various stages of min-
imal change nephrotic syndrome (MCNS), from six cases of
IgA nephropathy (IgAN) with high proteinuria and from seven
control kidneys. From each picture, the mean width of the foot
processes (FPW) was quantitated.
Results. In normal kidney the mean FPW was 580 ± 40 nm.
In biopsies from patients with MCNS without treatment, foot
processes were diffusely effaced, reflected by a FPW of 1600 ±
440 nm. In biopsies from patients with MCNS relapsing un-
der prednisolone treatment, foot processes were significantly
less effaced than in untreated MCNS (FPW 920 ± 200 nm).
In biopsies displaying IgAN, effacement was significantly more
segmental than in untreated MCNS (FPW 800 ± 170 nm). Pro-
teinuria did not differ significantly among the groups. Neither in
MCNS nor in IgAN was the extent of foot process effacement
correlated with the level of proteinuria.
Conclusion. Podocyte foot process effacement is not corre-
lated with proteinuria. The differences in podocyte effacement
between MCNS, MCNS relapsing under prednisolone treat-
ment, and IgAN may point to different mechanisms of podocyte
injury in these diseases.
Podocytes are highly specialized epithelial cells that
cover the glomerular basement membrane (GBM) with
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their numerous interdigitating foot processes. In combi-
nation with the GBM, podocytes constitute the filtration
barrier of the glomerular capillary wall. Proteinuria is
associated with striking changes in podocyte architec-
ture, as detected by electron microscopy. These changes
comprise of loss or effacement of the podocyte foot pro-
cesses. Podocyte foot process effacement can be the soli-
tary hallmark in the renal biopsy specimen, as in minimal
change nephrotic syndrome (MCNS), or can be accom-
panied by other abnormalities characteristic of the un-
derlying disease, such as immune deposits, inflammation,
or fibrosis [1]. Whether a solitary lesion or not, podocyte
foot process effacement seems a uniform response of the
podocyte to injury. The etiology of this phenomenon is as
yet unknown, despite the rapid increase in the knowledge
of podocyte structure and function over the last few years
[2]. Furthermore, how effacement of podocytes is related
to proteinuria and vice versa is a matter of debate.
To evaluate the relationship between proteinuria and
foot process effacement in human glomerulopathies, we
conducted a morphologic study on podocyte foot pro-
cesses in renal biopsies obtained from three groups of
patients with proteinuric glomerulopathies and in nor-
mal human kidney. Our findings may provide new insight
in the etiology of foot process effacement and proteinuria
in human glomerulopathies.
METHODS
Renal specimens and electron microscopy
Renal tissue was obtained for diagnostic purposes by
needle biopsies from 39 patients. The cases were diag-
nosed as MCNS (N = 27), proteinuric IgA nephropathy
(IgAN) (N = 6), or normal 6 to 12 months after transplan-
tation (control group) (N = 6). Additional control human
renal tissue was taken from an apparently unaffected part
of a kidney extirpated because of renal adenocarcinoma
(N = 1). At the time of the biopsy, 13 MCNS patients had
not yet received any immunosuppressive drugs, and 10
had relapsed under treatment with methylprednisolone.
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Fig. 1. Representative electron microscopy
images from the patient groups studied, used
for morphometric analysis of podocyte foot
process effacement. (A) Normal kidney, 6
months after transplantation. No proteinuria.
(B) Minimal change nephrotic syndrome. Pro-
teinuria 5 g/24 hours. (C) Minimal change
nephrotic syndrome, relapsing during treat-
ment with methylprednisolone. Proteinuria 4
g/24 hours. (D) IgA nephropathy. Proteinuria
6 g/24 hours. Scale 1:11,000. CL is capillary
lumen.
Four MCNS patients had achieved remission under treat-
ment with methylprednisolone. Since these patients ex-
perienced severe side effects, alternative treatment was
considered and a control biopsy was performed to
exclude focal segmental glomerulosclerosis (FSGS) le-
sions. Renal specimens were fixed in Karnovsky’s fix-
ative, postfixed in osmium tetroxide, and embedded in
epon (LADD Research Industries Inc., Williston, VT,
USA). The electron microscopy sections were stained
with uranyl acetate and lead citrate and examined with
a CM10 electron microscope (Philips, Eindhoven, The
Netherlands). For the present studies, 10 areas of one to
two glomeruli in each patient were photographed in a
random and unbiased fashion and printed on 23 × 23 cm
paper, giving a final magnification of 11,000-fold. To study
slit diaphragm morphology, random photographs were
taken at a final magnification of 108,000-fold.
Measurement of podocyte foot process effacement
and proteinuria
From each picture, the GBM was traced and measured
in an image processing and analysis program (Scion Cor-
poration, Frederick, MD, USA). The number of podocyte
foot processes along the GBM was counted by hand. A
foot process was defined as any connected epithelial seg-
ment butting on the basement membrane, between two
neighboring filtration pores or slits. From each photo-
graph, the arithmetic mean of the foot process width was
calculated as follows:
FPW =p
4
•
∑
GBM length
∑
foot process
where  foot process is the total number of foot processes
counted in each picture,  GBM length is the total GBM
length measured in each picture, and the correction factor
of p4 serves to correct for presumed random variation
in the angle of section relative to the long axis of the
podocyte [3]. For each patient, the mean width of the
foot processes (FPW) was calculated and that value was
used to finally calculate a mean FPW for each patient
group.
In all patients except the control group, proteinuria
was determined by measuring 24-hour excretion of to-
tal protein into the urine. Total protein was turbidimet-
rically determined using benzethoniumchloride. Urine
was collected within 2 days prior to the biopsy. In the
group of patients treated with steroids at the time of
biopsy, proteinuria was also determined within 2 days af-
ter the biopsy to ensure that proteinuria was persistent.
In the control group (absence of) albuminuria was deter-
mined using Albustix (Roche Diagnostics, Almere, The
Netherlands).
Statistical analysis
Differences between groups were determined by
Kruskal-Wallis tests, followed by Mann-Whitney tests to
calculate statistical significance. Differences were consid-
ered as significant when P < 0.05. Correlation analysis
was performed using the Spearman test.
RESULTS
Representative pictures from each patient group are
shown in Figure 1. From each case at least 400 lm GBM
was measured. The mean FPW in the individual pictures
ranged from minimally 430 nm to more than 6000 nm.
In normal kidneys, podocyte foot processes were well
conserved, yet segmental spreading of the processes was
present. The FPW in normal kidneys was 580 ± 40 nm
(Fig. 2A), which is in accordance with the normal range
described by others [4–6]. Podocyte foot processes from
MCNS patients in remission (i.e., without proteinuria)
were well conserved, resulting in a mean FPW of 660 ±
110 nm. In biopsies from patients with active MCNS with-
out treatment, podocyte foot processes were diffusely
effaced, reflected by a mean FPW of 1630 ± 440 nm.
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Fig. 2. Analysis of podocyte foot process effacement in the control
group and in the four patient groups, expressed as the mean width
of the podocyte foot processes (FPW). (A) Morphometric analysis of
minimal change nephrotic syndrome (MCNS). MCNS remission are
patients previously diagnosed as having MCNS; no proteinuria at the
time of biopsy. MCNS prednisolone are patients with MCNS relapsing
during treatment with methylprednisolone. IgA nephropathy (IgAN).
The error bars represent standard deviation. (B) Proteinuria in the three
proteinuric patient groups. In the control group and in the group of
MCN patients in remission at the time of biopsy, proteinuria was absent
by definition. The error bars represent standard deviation.
In biopsies from patients with MCNS relapsing under
methylprednisolone treatment, podocyte foot processes
were significantly more conserved than in untreated
MCNS (FPW 920 ± 200 nm, P < 0.001 versus untreated
MCNS). In biopsies displaying IgAN, effacement was
moderate and segmental, with a mean FPW of 805 ±
170 nm (P = 0.001 versus untreated MCNS). Importantly,
proteinuria did not differ significantly between the pro-
teinuric groups (P = 0.38) (Fig. 2B).
The individual FPW values of proteinuric patients are
depicted in Figure 3. Neither in active MCNS nor in IgAN,
FPW was correlated to proteinuria (r = 0.05 for untreated
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Fig. 3. Proteinuria versus podocyte foot process effacement in the indi-
vidual proteinuric patients studied. In none of the patient groups there
was a correlation between proteinuria and podocyte foot process ef-
facement (see text for values).
MCNS, P = 0.87; r = 0.50 for MCNS under prednisolone
treatment, P = 0.11; r = −0.23 for IgAN, P = 0.66). A
correlation was also absent when all proteinuric MCNS
patients were considered one group (r = 0.25, P = 0.25),
or when all proteinuric patients were grouped together
(r = 0.34, P = 0.07).
MCNS has been reported to be associated not only with
podocyte foot process effacement, but also with distor-
tion of the slit diaphragms. In accordance with reports by
others [7, 8], we observed diffusely distorted filtration slits
in our MCNS patients, with displacement of the deformed
slits toward the apical cell membrane of the foot processes
and the formation of occluding junctional complexes be-
tween neighboring foot processes elsewhere (Fig. 4C).
Also, the interpedical spaces were irregularly widened or
even absent when junctions were formed. In contrast, the
changes in slit diaphragm morphology in MCNS patients
relapsing under prednisolone treatment were less exten-
sive and limited to the effaced podocyte foot processes.
The slit diaphragms that connected conserved foot pro-
cesses appeared normal (Fig. 4D and E). Also in IgAN
patients, damage to the slit diaphragms was only focal
and mainly apparently normal slits could be observed
(Fig. 4F).
DISCUSSION
In 1957, Farquhar et al [7] were the first to describe
extensive effacement of podocyte foot processes in biop-
sies of patients with nephrotic syndrome. Foot process
effacement has since been documented by many authors
and has been subject of extensive investigation in hu-
mans and in animal models. Despite this, the pathogen-
esis of podocyte foot process effacement and its relation
to proteinuria are still not clear. Podocyte foot process
effacement seems a stereotypic reaction of podocytes to
damage [1]. In laboratory animals, there are various ways
to induce foot process effacement and proteinuria by
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Fig. 4. Slit diaphragm morphology in the patient groups studied. The small arrows indicate slit diaphragms. (A) Normal kidney, 6 months after
transplantation, with intact slit diaphragms. (B) Minimal change nephrotic syndrome in remission under treatment with methylprednisolone, with
intact slit diaphragms. (C) Minimal change nephrotic syndrome. Proteinuria 11 g/24 hours. Note the ladder-like slit diaphragm that is displaced toward
the apical pole of the cells (large arrow). (D and E) Minimal change nephrotic syndrome, relapsing during treatment with methylprednisolone.
Proteinuria 5 g/24 hours (D) and 8 g/24 hours (E), respectively. Slit diaphragms are largely normal (see text). In (E) the classical zipper-like
morphology of the slit diaphragm as firstly reported by Rodewald and Karnovsky [33] is detected by tangential sectioning (arrowhead). (F) IgA
nephropathy. Proteinuria 5 g/24 hours. Slit diaphragms are largely intact. Scale 1:108,000 (A to D and F) and 1:150,000 (E).
injuring podocytes. The velocity of development of foot
process effacement and its severity differ between the
models. Examples are immune complex–mediated injury
by complement in the Heymann-nephritis model [9, 10],
direct toxic podocyte injury by puromycin aminonucle-
oside [11, 12] or adriamycin [13, 14], and injury by in-
jecting antibodies directed against distinct epitopes on
podocytes, such as podoplanin [15] and aminopeptidase
A [16]. Studies on knockout mice have shown that also
genetic disruption of genes encoding structural compo-
nents of the podocyte foot process or slit diaphragm can
lead to podocyte foot process effacement and knockout
phenotypes have also been identified in human forms of
hereditary nephrotic syndromes (as reviewed in [17]). Al-
though the initial cause leading to foot process efface-
ment in those models and diseases may seem evident, its
relation to the development of proteinuria is still not fully
understood.
The pathogenic mechanism underlying podocyte foot
process effacement in acquired nephrotic syndromes,
such as MCNS, primary FSGS, or nephrotic syndrome
in the context of IgAN is unknown. In analogy to animal
models, different pathogenic mechanisms may underlie
proteinuria and foot process effacement also in acquired
human glomerulopathies.
During routine examination of electron micrographs
of human renal biopsy tissue, we were struck by differ-
ences in the degree of podocyte foot process effacement
in biopsies from nephrotic patients with comparable lev-
els of proteinuria. To validate these differences and to
further evaluate the relationship of podocyte foot process
effacement and proteinuria, this study was undertaken.
Morphometric analysis confirmed that there were
significant differences in the degree of foot process efface-
ment between patients with MCNS, MCNS relapsing un-
der prednisolone treatment and IgAN. These differences,
however, were independent of the level of proteinuria.
Although an abnormal foot process width was invariably
associated with proteinuria, a rather large fraction of pa-
tients with relapsing MCNS and IgAN presenting with
gross proteinuria had only segmental to moderate efface-
ment of the podocyte foot processes. This is in line with
other studies, both in animals and in humans, showing
that proteinuria is not uniformly associated with podocyte
foot process effacement. After injection of monoclonal
antibodies directed against slit diaphragm components
nephrin or neph1, rats rapidly develop proteinuria in the
presence of intact foot processes [18, 19]. Male MWF
rats develop spontaneous proteinuria with age, without
changes in the podocyte foot processes [20]. In humans, a
familial form of nephrotic syndrome has been reported to
occur in the absence of effacement of the podocyte foot
processes [21] and in patients with glomerulonephritis,
proteinuria is not always associated with foot process ef-
facement [22].
We did not find a correlation between proteinuria and
foot process effacement in nephrotic patients, in contrast
to two previous studies that described weak but signif-
icant correlations between foot process effacement and
proteinuria in MCNS patients [4, 6]. It should be stated
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that the correlations in both studies were calculated by
considering all MCNS patients as one group (i.e., includ-
ing a significant number of patients who were treated with
prednisolone and patients achieving remission, thereby
presenting with proteinuria less than 1 g/24 hours). Only
when we would also consider all MCNS patients as one
group, including patients in remission (without protein-
uria), we would indeed find a weak, yet significant cor-
relation (r = 0.52; P = 0.028). To our opinion, however,
this only shows that in patients who achieve remission,
podocytes return to their normal shape and that ab-
normal foot process width is invariably associated with
proteinuria.
In an attempt to explain the occurrence of proteinuria
in the absence of extensive foot process effacement, we
studied the morphology of the podocyte slit diaphragms.
The slit diaphragm represents an intercellular junction
and not only forms a functional filter, but also estab-
lishes the contact between two adjacent foot processes
which are derived from two different podocytes. The crit-
ical role of the slit diaphragm in the maintenance of the
glomerular filtration barrier is highlighted by the dis-
covery that forms of familial nephrotic syndrome are
caused by aberrant expression of the slit diaphragm con-
stituents nephrin [23] and podocin [24]; genetic disruption
of these and other slit diaphragm components and intra-
cellular slit diaphragm linker proteins, such as neph1 and
CD2AP, concordantly results in proteinuria in mice [25–
28]. The pathogenic role of these slit diaphragm proteins
in MCNS, a nonfamilial disease, is still not elucidated.
Morphologically, the slit diaphragms in MCNS biopsies
are dislocated, apparently absent or replaced by junc-
tions [7, 8] (Fig. 4B). In contrast, we found that the slit
diaphragms appeared largely preserved in the group of
patients relapsing under prednisolone treatment and in
IgAN patients. Intact slit diaphragms were observed in
conjunction with intact foot processes; only focally, dam-
aged slit diaphragms were present. Thus, in these patients,
proteinuria could not be explained by overt damage to the
podocyte slit diaphragms. We next examined glomerular
expression of podocin and nephrin by immunofluores-
cence on cryostat sections that were available from the
patients presented here. The expression of podocin ap-
peared normal in all groups, showing a linear distribution
along the peripheral capillary loops of the glomeruli (not
shown). The distribution of nephrin showed also a linear
glomerular pattern in most groups. Only in patients with
untreated MCNS, the staining pattern of nephrin was al-
tered into a more granular pattern (not shown), which
is in line with earlier studies [6]. Thus, the differences
in foot process effacement between the groups reported
here cannot be explained by differences in podocin ex-
pression. Furthermore, nephrin protein expression ap-
pears to be correlated with the extent of podocyte foot
process effacement.
In summary, our study confirms that proteinuria, foot
process effacement, and slit diaphragm damage are
associated, yet neither foot process effacement nor slit
diaphragm damage seem to be a prerequisite for pro-
teinuria. The lack of correlation between proteinuria and
foot process effacement renders an exclusive causal rela-
tionship between podocyte foot process effacement and
proteinuria unlikely. A potential causal relationship may
be present in the protein overload model, in which in-
jection of rats with large doses of bovine serum albu-
min causes proteinuria associated with podocyte foot
process effacement [29, 30]. The possibility of injury of
podocytes by albumin itself cannot be excluded, yet our
findings suggest that such a mechanism is not likely in the
glomerulopathies studied here. Our results support our
hypothesis that the extent of foot process effacement is
determined by the mechanism of injury, supposing a dif-
ferent nature of podocyte injury in MCNS and IgAN.
The latter may not be unexpected, yet we also found
striking differences between MCNS patients relapsing
under prednisolone treatment and those not receiving
prednisolone at the time of biopsy. Patients frequently
relapsing under prednisolone treatment, thus called
steroid-dependent, make up about 30% of the MCNS pa-
tients [31] and thus constitute an important clinical prob-
lem. To maintain remission these patients require high
doses of steroids, resulting in toxic side-effects. It has re-
cently been shown that not only familial cases, but also
some sporadic cases of steroid-resistant nephrotic syn-
drome can be caused by mutations in the gene encoding
podocin [32]. Those patients usually show no response
to immunosuppressive treatment and progress to FSGS,
which was not observed in our patients. Also, the renal
expression of podocin was normal in our patients, as de-
tected by immunofluorescence (not shown). Therefore,
the steroid-dependent patients presented here seem to
represent a distinct patient group, with a specific hall-
mark in the renal biopsy (i.e., limited foot process ef-
facement and preservation of slit diaphragms), in the
presence of proteinuria. In the future this feature might
help to identify patients that require treatment dif-
ferent from steroids, such as cyclosporine, cyclophos-
phamide and levamisole, and thus deserves further
investigation.
CONCLUSION
The severity of foot process effacement in biopsies of
nephrotic patients is dependent on the nature of the un-
derlying disease and is independent on the level of pro-
teinuria. It appears that podocyte foot process effacement
and proteinuria are independent sequelae of injury to the
glomerular filtration barrier. For acquired nephrotic syn-
dromes, the nature of the initiating injury remains to be
identified.
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